Literature DB >> 11709364

Inhibition of herpes simplex virus reactivation by dipyridamole.

R B Tenser1, A Gaydos, K A Hay.   

Abstract

Herpes simplex virus (HSV) reactivation from latency was investigated. Reactivation of thymidine kinase-negative HSV, which is defective for reactivation, was greatly enhanced by thymidine (TdR). The reactivation-enhancing effect of TdR was blocked by dipyridamole (DPM), a known nucleoside transport inhibitor. DPM also inhibited wild-type HSV reactivation, suggesting potential antiviral use.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11709364      PMCID： PMC90893          DOI： 10.1128/AAC.45.12.3657-3659.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  The role of herpes simplex virus type 1 thymidine kinase in pathogenesis.

Authors:  S Efstathiou; S Kemp; G Darby; A C Minson
Journal:  J Gen Virol       Date:  1989-04       Impact factor: 3.891

2.  Latency-associated transcript but not reactivatable virus is present in sensory ganglion neurons after inoculation of thymidine kinase-negative mutants of herpes simplex virus type 1.

Authors:  R B Tenser; K A Hay; W A Edris
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

Review 3.  Dipyridamole.

Authors:  G A FitzGerald
Journal:  N Engl J Med       Date:  1987-05-14       Impact factor: 91.245

Review 4.  Recent advances in the molecular biology of nucleoside transporters of mammalian cells.

Authors:  C E Cass; J D Young; S A Baldwin
Journal:  Biochem Cell Biol       Date:  1998       Impact factor: 3.626

5.  A common basis for inhibition of nucleoside transport by dipyridamole and nitrobenzylthioinosine?

Authors:  A R Paterson; E Y Lau; E Dahlig; C E Cass
Journal:  Mol Pharmacol       Date:  1980-07       Impact factor: 4.436

6.  Effect of dipyridamole on transport and phosphorylation of thymidine and 3'-azido-3'-deoxythymidine in human monocyte/macrophages.

Authors:  G V Betageri; J Szebeni; K Hung; S S Patel; L M Wahl; M Corcoran; J N Weinstein
Journal:  Biochem Pharmacol       Date:  1990-08-15       Impact factor: 5.858

7.  Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages.

Authors:  J Szebeni; S M Wahl; M Popovic; L M Wahl; S Gartner; R L Fine; U Skaleric; R M Friedmann; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate.

Authors:  D M Coen; M Kosz-Vnenchak; J G Jacobson; D A Leib; C L Bogard; P A Schaffer; K L Tyler; D M Knipe
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Acyclovir transport into human erythrocytes.

Authors:  W B Mahony; B A Domin; R T McConnell; T P Zimmerman
Journal:  J Biol Chem       Date:  1988-07-05       Impact factor: 5.157

10.  Effects of nucleoside transport inhibitors on the salvage and toxicity of adenosine and deoxyadenosine in L1210 and P388 mouse leukemia cells.

Authors:  P G Plagemann; R M Wohlhueter
Journal:  Cancer Res       Date:  1985-12       Impact factor: 12.701
View more
  14 in total

1.  Base catalyzed multicomponent synthesis of spiroheterocycles with fused heterosystems.

Authors:  Anand Kumar Arya; Mahendra Kumar
Journal:  Mol Divers       Date:  2011-03-20       Impact factor: 2.943

2.  Design, Synthesis and Biological Evaluation of Novel Pyrimido[4,5-d]pyrimidine CDK2 Inhibitors as Anti-Tumor Agents.

Authors:  Samir M El-Moghazy; Diaa A Ibrahim; Nagwa M Abdelgawad; Nahla A H Farag; Ahmad S El-Khouly
Journal:  Sci Pharm       Date:  2011-05-08

3.  Dipyridamole reversibly inhibits mengovirus RNA replication.

Authors:  Cori L Fata-Hartley; Ann C Palmenberg
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.

Authors:  Moshe Rogosnitzky; Esther Berkowitz; Alejandro R Jadad
Journal:  JMIRx Med       Date:  2020-09-30

Review 5.  Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors.

Authors:  Shenghua Gao; Tianguang Huang; Letian Song; Shujing Xu; Yusen Cheng; Srinivasulu Cherukupalli; Dongwei Kang; Tong Zhao; Lin Sun; Jian Zhang; Peng Zhan; Xinyong Liu
Journal:  Acta Pharm Sin B       Date:  2021-08-31       Impact factor: 11.413

Review 6.  COVID-19 and thrombotic complications-the role of anticoagulants, antiplatelets and thrombolytics.

Authors:  Gaurav Khandelwal; Avik Ray; Samdish Sethi; H K Harikrishnan; Chaitanya Khandelwal; Balakrishnan Sadasivam
Journal:  J Family Med Prim Care       Date:  2021-11-05

7.  Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.

Authors:  Kholoud F Aliter; Rami A Al-Horani
Journal:  Curr Pharm Des       Date:  2021       Impact factor: 3.116

8.  Facile construction of substituted pyrimido[4,5-d]pyrimidones by transformation of enaminouracil.

Authors:  Wafaa S Hamama; Mohamed A Ismail; Hanaa A Al-Saman; Hanafi H Zoorob
Journal:  J Adv Res       Date:  2012-05-16       Impact factor: 10.479

9.  Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.

Authors:  James J DiNicolantonio; Jorge Barroso-Aranda
Journal:  Med Hypotheses       Date:  2020-07-02       Impact factor: 1.538

Review 10.  Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.

Authors:  Nadia Alice Vieira Motta; Lis Jappour Autran; Stephani Correia Brazão; Rosane de Oliveira Lopes; Christianne Brêtas Vieira Scaramello; Gabriel Ferreira Lima; Fernanda Carla Ferreira de Brito
Journal:  Int Immunopharmacol       Date:  2020-12-28       Impact factor: 5.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.